On December 29, 2020, the coming into force date for the amended PMPRB regulations and guidelines were further delayed to July 1, 2021.  The PMPRB has invited stakeholders to comment on two critical amendments to the regulations with responses due by February 15th. Specifically, the PMPRB proposes to change the definition of Gap medicines and the timeline for compliance with the Maximum List Price (MLP) ceiling for Grandfathered and Gap medicines.

PDCI strives to support timely transparency around public policy consultations and invites organizations and individuals to share their submissions here so ideas may be shared publicly. PDCI has begun collecting responses and will soon be posting stakeholder comments on the PDCI response sharing page.  

Please e-mail Jennifer Mathews, Manager Pricing Data, at Jennifer.mathews@pdci.ca with a PDF version of your response including consent for PDCI to publish the response on its website. 

Thank you to all stakeholders who shared their responses.

Note: PMPRB may publish all submissions it receives as part of this consultation, however timing for this is not yet clear. Once PMPRB publishes the comprehensive set of submissions, PDCI’s sharing page will direct visitors to the comprehensive set of submissions on the PMPRB website.